Stryker Corporation reports developments as a global medical technology company serving MedSurg, Neurotechnology and Orthopaedics markets. Company news commonly covers operating results, organic sales trends, segment performance, dividends, shareholder-meeting activity and executive finance or investor-relations appointments.
Stryker updates also address portfolio expansion across medical devices, implants, instruments, operating-room equipment, neurotechnology and vascular solutions. Recent corporate activity includes the completed acquisition of Amplitude Vascular Systems, adding an intravascular lithotripsy platform for peripheral arterial disease to Stryker's peripheral vascular portfolio.
Stryker (NYSE: SYK) has completed the acquisition of care.ai, a privately held company specializing in AI-assisted virtual care workflows, smart room technology, and ambient intelligence solutions. This acquisition is expected to strengthen Stryker's growing healthcare IT offering and wirelessly connected medical device portfolio. Andy Pierce, Group President of MedSurg and Neurotechnology at Stryker, expressed enthusiasm about accelerating the company's digital vision to provide customers with real-time, smart, and connected decision-making tools that can enhance the lives of caregivers and their patients. The acquisition aligns with Stryker's strategy to expand its technological capabilities in the healthcare sector.
Politan Capital Management, an 8.9% shareholder of Masimo (NASDAQ: MASI), has issued an open letter to shareholders ahead of the company's 2024 Annual Meeting on September 19. The letter highlights the need for further change in Masimo's boardroom and refutes the company's defensive rhetoric. Politan urges shareholders to vote for its independent nominees, Darlene Solomon and William Jellison, on the WHITE card.
Key points from the letter include:
- Criticism of Masimo's board for lack of oversight and transparency
- Allegations of collusion between Masimo's CEO and RTW to manipulate voting
- Refutation of Masimo's claims about potential business disruption
- Defense against Masimo's accusations towards Politan
- Emphasis on the urgent need for change in Masimo's governance
Politan argues that without a majority of independent directors, Masimo's pattern of poor governance and shareholder value destruction will continue.
Eko Health, a leader in AI-powered early detection of heart and lung diseases, has appointed Brent D. Lang to its Board of Directors. Lang, former Chairman and CEO of Vocera Communications, brings over 30 years of healthcare and technology experience. He led Vocera through rapid growth, a successful IPO, and its $3 billion acquisition by Stryker (NYSE: SYK).
This appointment follows Eko's recent achievements, including surpassing 500,000 healthcare providers on its platform, completing a $41 million Series D funding round, and receiving FDA clearance for an AI algorithm aiding heart failure detection during routine exams. Lang's strategic vision is expected to guide Eko's continued innovation and expansion in early disease detection technology.
Stryker (NYSE:SYK) has expanded its Foot & Ankle portfolio with two new products: the Osteotomy Truss System™ (OTS) and Ankle Truss System™ (ATS), acquired from 4WEB Medical. These innovations will be showcased at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting in Vancouver from Sept. 11-14, 2024.
The ATS, featuring Arthrosphere® and Arthrocube™ implants, is designed for tibiotalocalcaneal fusions, offering structural support and promoting fusion. The OTS provides a comprehensive solution for osteotomy needs. Stryker will also highlight the Artelon Flexband and celebrate the 10th anniversary of the Infinity Total Ankle System, which boasts a 95.9% survivorship rate at seven years.
Stryker (NYSE: SYK) has announced a definitive agreement to acquire Vertos Medical Inc., a private company specializing in minimally invasive treatments for chronic lower back pain caused by lumbar spinal stenosis. This acquisition aims to expand Stryker's interventional pain management solutions, particularly in ambulatory surgery centers.
Vertos Medical's mild® procedure offers pain relief and improved mobility without major surgery, addressing a condition affecting millions globally. Andy Pierce, Group President at Stryker, emphasized the company's commitment to restoring patients' quality of life through interventional solutions. The transaction, subject to customary closing conditions, is expected to strengthen Stryker's portfolio in the growing field of minimally invasive pain management.
Stryker (NYSE:SYK), a leading medical technology company, has announced its participation in the 2024 Wells Fargo Healthcare Conference. The event is scheduled for Thursday, September 5, at the Encore Boston Harbor. Representing Stryker will be Spencer Stiles, Group President of Orthopaedics and Spine, and Jason Beach, Vice President of Finance and Investor Relations.
Their presentation is set for 3:00 pm Eastern Time. Investors and interested parties can access a live webcast of the presentation on Stryker's official website. For those unable to attend or watch live, a replay will be available on the company's Investor Relations page. This conference provides Stryker an opportunity to showcase its latest developments and strategies in the healthcare technology sector.
Stryker (NYSE: SYK) has announced a definitive agreement to acquire care.ai, a privately held company specializing in AI-assisted virtual care workflows, smart room technology, and ambient intelligence solutions. This acquisition aims to strengthen Stryker's healthcare IT offering and wirelessly connected medical device portfolio.
The integration of care.ai's technology with Stryker's Vocera platform and devices will create an enterprise-wide ecosystem capable of delivering dynamic clinical workflows and advancing smart care facilities. This move is particularly significant as Stryker's customers face challenges such as nursing shortages, employee retention issues, and workplace safety concerns.
The acquisition is subject to customary closing conditions, and both companies will operate separately until the transaction closes.
Stryker (NYSE:SYK), a leading medical technology company, has announced a quarterly dividend of $0.80 per share. This dividend represents a 6.7% increase compared to the previous year, while remaining unchanged from the last quarter. The dividend will be payable on October 31, 2024 to shareholders of record as of the close of business on September 30, 2024. This announcement demonstrates Stryker's commitment to returning value to its shareholders and reflects the company's financial stability and confidence in its future performance.
Stryker (NYSE: SYK) has launched its Pangea Plating System, which received FDA clearance in late 2023. The system offers a comprehensive and versatile portfolio for variable-angle plating across various patient populations. It is designed for internal fixation and stabilization of bone fractures, osteotomies, and arthrodesis in normal and osteopenic bone.
Key features of the Pangea Plating System include:
- Evidence-based design for improved implant fit
- Enhanced plate fit and screw placement
- Anatomically contoured implants for diverse fracture patterns
- 20 anatomic plates and 13 utility plates in one platform
- Intuitive and streamlined instrumentation
Stryker will host 'The Pangea Experience' event on August 9-10, 2024, in Las Vegas to showcase this new technology and offer insights to customers.
Stryker (NYSE:SYK) has completed the acquisition of MOLLI Surgical Inc., a private company specializing in wire-free soft tissue localization technology for breast conserving surgery. This acquisition strengthens Stryker's commitment to advancing surgical solutions in breast cancer care. The MOLLI 2 localization system offers ease of use and reliability for efficient surgical workflows. Key features include:
- MOLLI Marker: Smallest on the market at 3.2 mm, detectable in dense breasts and through hematoma
- MOLLI 2 tablet: Provides surgeons with real-time feedback including distance, visual, auditory, and 3D directional guidance
This acquisition complements Stryker's existing breast cancer portfolio, which includes SPY fluorescence imaging technology for lymphatic mapping and lighted retractors.